查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008498

神经退化性疾病治疗市场：按类型、药物类别、给药途径、作用机制、治疗方法、适应症、患者群体、销售管道和最终用户划分－2026-2032年全球市场预测

Neurodegenerative Drugs Market by Type, Drug Class, Mode Of Administration, Mechanism Of Action, Therapeutic Approach, Indication, Patient Demographics, Sales Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，神经退化性疾病治疗市场价值将达到 477.9 亿美元，到 2026 年将成长至 513.9 亿美元，到 2032 年将达到 815.1 亿美元，复合年增长率为 7.92%。

主要市场统计数据
基准年 2025 477.9亿美元
预计年份：2026年 513.9亿美元
预测年份 2032 815.1亿美元
复合年增长率 (%) 7.92%

本文将揭示在史无前例的科学和政策变革中，神经退化性疾病治疗的研究和市场发展的基础。

在全球人口老化和疾病机制复杂多样的背景下，神经退化性疾病已成为现代医疗保健面临的最复杂挑战之一。阿兹海默症、帕金森氏症、肌萎缩性侧索硬化症（ALS）和多发性硬化症等疾病日益增多，亟需开发新的治疗策略，同时缓解症状并延缓疾病进展。为了因应这些需求，分子生物学、基因编辑和生物标记发现领域的突破性进展正在重新定义药物研发的典范。

本文探讨了神经退化性疾病治疗领域发生的变革性变化，这些变化是由突破性发现和对监管框架的根本性重新评估所驱动的。

神经退化性疾病治疗领域正经历着一场翻天覆地的变革，主要得益于科学的进步和监管理念的转变。精准医疗的发展使得人们能够发现新的分子标靶，并开发出能够延缓或阻止疾病进展的治疗方法。基因疗法、单株抗体和小分子调变器的创新正在开闢前所未有的干预途径。同时，主要市场的监管机构也意识到饱受神经系统疾病折磨的患者的迫切需求，并正在推行扩大适应症许可和有条件核准。

检验2025 年美国关税对神经退化性疾病治疗的供应链、定价结构和全球竞争力的累积影响。

美国将于2025年实施关税，这将为神经退化性疾病治疗药物的供应链带来新的复杂性，原料药）和成品均产生影响。依赖跨国采购的製造商正面临原物料成本上涨的困境，由此产生的价格压力波及整个经销网络。为因应这项挑战，各公司正努力重组供应链，并透过探索替代采购途径和加强国内生产能力来缓解关税带来的成本上涨。

关键的市场细分洞察，可指导药物类型、分类、给药途径和患者群体的策略定位。

精准理解市场区隔对于优化神经退化性疾病治疗领域的研发投资和商业化策略至关重要。分析药物类型可以发现不同的价值提案，尤其是在品牌药和学名药之间。创新品牌药组合维持高溢价，而学名药提供了经济实惠的治疗途径。就药物类别而言，胆碱酯酶抑制剂（如多奈哌齐、吡啶斯的明和Rivastigmine）在维持认知功能方面发挥关键作用，而脱羧酶抑制剂（如芐丝肼、碳度巴和甲基多巴）则与多巴胺促效剂（如阿扑吗啡、卡麦角林、Pramipexole和rotigotine）形成互补。免疫调节药物透过标靶缓解疾病通路，为治疗增添了新的维度。

阐明影响主要地区神经退化性疾病治疗引进模式和投资重点的关键区域动态因素。

区域趋势对神经退化性疾病治疗药物的引进和投资有显着影响。在美洲，完善的研究基础设施和大量的公共及私人资金正在加速尖端疗法的开发，而成熟的医保报销体系则为商业性扩张提供了支持。该地区的市场参与企业正在利用先进的临床试验网路和上市后调查计画来检验真实世界的临床结果，并提升市场进入。

引领神经退化性疾病治疗市场创新、伙伴关係和竞争策略的主要企业。

在神经退化性疾病治疗领域，一些机构因其在研发和商业化方面的开创性方法而脱颖而出。这些行业领导者充分利用跨学科合作，并将学术知识与自身研发能力结合，从而加速候选化合物的筛选和临床前检验。透过与生物技术公司和技术供应商建立策略合作伙伴关係，他们能够利用先进的分析技术和人工智慧来优化临床试验设计和患者招募策略。

为产业领导者制定切实可行的策略建议，以因应不断变化的市场环境和监管环境。

要在瞬息万变的神经退化性疾病治疗领域取得成功，产业领导者需要采取多管齐下的策略方针。首先，优先投资于前沿倡议项目，例如基因疗法、生物标记主导平台以及与数位医疗的整合，能够使企业始终处于创新前沿。其次，透过建立区域性製造地和签订替代采购合约来实现供应链多元化，可以降低关税波动和地缘政治变化带来的财务和营运风险。

详细介绍了整合多维资料来源、专家分析和严格检验过程的稳健调查方法。

本研究采用综合调查方法，旨在提供切实可行的见解和可靠的分析。研究基于广泛的二手资料研究，包括同行评审期刊、监管文件和临床试验资料库，从而了解神经退化性疾病药物研发的现状。在此基础上，研究也与包括神经科医生、药理学家和患者权益组织代表在内的关键意见领袖（KOL）开展了一手调查，以深入观点治疗需求和药物应用趋势。

整合关键见解和策略意义，以指导神经退化性疾病领域中相关人员的决策。

这项分析的综合结果凸显了神经退化性疾病治疗发展正在发生变革性变化。分子标靶和生物标记识别的科学突破，与加速患者获得治疗的监管创新相辅相成。同时，在不断变化的关税政策和供应链趋势下，适应性强的商业策略对于维持成本效益和全球竞争力至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：神经退化性疾病治疗市场：依类型划分

  • 品牌商品
  • 学名药

第九章：神经退化性疾病治疗市场：依药物类别划分

  • 胆碱酯酶抑制剂
    • 多奈哌齐
    • 吡啶斯的明
    • Rivastigmine
  • 脱羧酶抑制剂
    • 芐丝肼
    • 碳度巴
    • 甲基多巴
  • 多巴胺促效剂
    • 阿扑吗啡
    • 卡麦角林
    • Pramipexole
    • rotigotine
  • 免疫调节药物

第十章：依给药途径分類的神经退化性疾病治疗药物市场

  • 注射药物
  • 口服
  • 经皮贴剂

第十一章：按作用机转分類的神经退化性疾病治疗药物市场

  • 离子通道调变器
    • 钾通道调变器
    • 钠通道调变器
  • 突触调变器

第十二章：依治疗方法分類的神经退化性疾病治疗市场

  • 神经保护
    • 抗发炎药
    • 抗氧化剂
  • 预防性治疗
  • 症状治疗

第十三章：神经退化性疾病治疗市场：依适应症划分

  • 阿兹海默症
  • 肌萎缩侧索硬化症（ALS）
  • 多发性硬化症
    • 原发性进行性
    • 復发缓解型
  • 帕金森氏症

第十四章：依病患细分分類的神经退化性疾病治疗市场

  • 成人版
  • 老年人
  • 儿童

第十五章：神经退化性疾病治疗市场：依销售管道划分

  • 离线
    • 医院和药房
    • 零售药房
  • 在线的

第十六章：神经退化性疾病治疗市场：依最终用户划分

  • 诊所
  • 合约研究机构
  • 医院
  • 研究机构

第十七章：神经退化性疾病治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十八章：神经退化性疾病治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十九章：神经退化性疾病治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第20章：美国神经退化性疾病治疗药物市场

第21章：中国神经退化性疾病治疗药物市场

第22章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • ACADIA Pharmaceuticals Inc.
  • Alpha Cognition Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aquinnah Pharmaceuticals Inc.
  • Asceneuron SA
  • AstraZeneca PLC
  • AZTherapies, Inc.
  • Bausch Health Companies Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Denali Therapeutics Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin International plc
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation by Smiths Group plc
  • Pfizer, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma
  • UCB SA
Product Code: MRR-C002B1C996F9

The Neurodegenerative Drugs Market was valued at USD 47.79 billion in 2025 and is projected to grow to USD 51.39 billion in 2026, with a CAGR of 7.92%, reaching USD 81.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 47.79 billion
Estimated Year [2026] USD 51.39 billion
Forecast Year [2032] USD 81.51 billion
CAGR (%) 7.92%

Unveiling the Foundations of Neurodegenerative Drug Research and Market Evolution Amidst Unprecedented Scientific and Policy Disruptions

Neurodegenerative disorders present one of the most complex challenges to modern healthcare, driven by an aging global population and multifactorial disease mechanisms. Conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis have propelled the need for novel therapeutic strategies that address both symptoms and underlying disease progression. Amid this imperative, breakthroughs in molecular biology, gene editing, and biomarker discovery are redefining the paradigms of drug development.

At the same time, regulatory landscapes are evolving to accommodate accelerated approval pathways and expanded access frameworks, creating a more flexible environment for innovators to bring therapies to patients in need. The integration of real-world evidence and digital health platforms has enhanced clinical trial design, enabling more precise patient stratification and adaptive study protocols. Collaborative models between academic institutions, biotechnology startups, and established pharmaceutical companies are further accelerating the translation of preclinical insights into clinical candidates.

Looking ahead, the focus is shifting towards holistic approaches that combine neuroprotection, immunomodulation, and synaptic support. Stakeholders are increasingly evaluating combination therapies and leveraging artificial intelligence to optimize drug discovery pipelines. This introduction sets the stage for an in-depth exploration of the transformative shifts, policy impacts, segmentation nuances, regional dynamics, and strategic imperatives that define the future of neurodegenerative drug development.

Tracing the Transformative Shifts in Neurodegenerative Therapy Landscape Fueled by Breakthrough Discoveries and Regulatory Overhauls

The neurodegenerative drug landscape is undergoing a profound metamorphosis, catalyzed by converging scientific advances and shifts in regulatory philosophy. Precision medicine initiatives have identified novel molecular targets, enabling the development of therapies that may slow or halt disease progression. Innovations in gene therapy, monoclonal antibodies, and small molecule modulators are offering unprecedented avenues for intervention. Concurrently, regulatory bodies across major markets have introduced adaptive licensing schemes and conditional approvals, recognizing the urgent unmet needs of patients affected by debilitating neurological conditions.

In parallel, technological advancements in imaging, fluid biomarkers, and omics analytics are refining diagnostic criteria and enabling earlier intervention. Digital therapeutics and remote monitoring devices are enhancing patient engagement and supporting data-driven decision making. This ecosystem of innovation has fostered strategic alliances, where biopharma companies collaborate with technology firms to co-develop integrated solutions that extend beyond traditional pharmacotherapy.

As a result, clinical trial paradigms are evolving towards decentralized models and master protocols, reducing time to market and improving the efficiency of patient recruitment. These transformative shifts not only accelerate access to cutting-edge treatments but also redefine competitive dynamics, compelling stakeholders to reevaluate their pipelines, partnerships, and go-to-market strategies in light of an increasingly agile and patient-centric environment.

Examining the Cumulative Effects of 2025 US Tariffs on Neurodegenerative Drug Supply Chains, Pricing Structures, and Global Competitiveness

The implementation of United States tariffs in 2025 has introduced a new layer of complexity to the neurodegenerative drug supply chain, impacting both active pharmaceutical ingredients and finished formulations. Manufacturers reliant on cross-border sourcing have encountered elevated input costs, leading to pricing pressures that reverberate throughout distribution networks. In response, companies have initiated supply chain realignment efforts, exploring alternative procurement corridors and reinforcing domestic manufacturing capabilities to mitigate tariff-driven cost escalations.

These developments have altered global competitiveness, particularly for firms exporting to or from regions with disparate tariff frameworks. Negotiations with contract manufacturing organizations and distribution partners now emphasize risk-sharing arrangements and flexible contract terms to absorb additional financial burdens. At the same time, pricing committees and reimbursement agencies are closely monitoring tariff-induced cost fluctuations, requiring more transparent cost-justification frameworks.

Looking forward, industry players are increasingly adopting dynamic pricing strategies and leveraging trade agreements to optimize cross-border operations. Collaboration with regulatory authorities and trade bodies has become essential to navigate evolving tariff schedules and to advocate for policy adjustments that recognize the critical nature of neurodegenerative therapies. This analysis highlights the cumulative impact of tariff policies on market dynamics, underscoring the need for adaptive supply chain resilience and strategic cost management.

Illuminating Critical Market Segmentation Insights That Inform Strategic Positioning Across Drug Types Classes Administration Modes and Patient Profiles

A nuanced understanding of market segmentation is essential for tailoring R&D investments and commercialization strategies within the neurodegenerative drug space. When examined by type, the distinction between branded and generic therapies reveals divergent value propositions, with innovative brand portfolios commanding premium pricing while generics offer cost-effective access. Within drug classes, cholinesterase inhibitors such as donepezil, pyridostigmine and rivastigmine play a key role in cognitive support, whereas decarboxylase inhibitors like benserazide, carbidopa and methyldopa complement dopamine agonists including apomorphine, cabergoline, pramipexole and rotigotine. Immunomodulators add another dimension by targeting disease-modifying pathways.

Mode of administration further segments the market into injectable, oral, and transdermal patch formats, influencing patient adherence and route-specific efficacy. Mechanisms of action are delineated between ion channel modulators-spanning potassium and sodium channel regulators-and synaptic modulators that address neurotransmitter dynamics. Therapeutic approaches divide into neuroprotection, preventive treatment and symptomatic relief, with neuroprotective strategies encompassing anti-inflammatory agents and antioxidants. Indication-based segmentation highlights applications in Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis-with primary progressive and relapsing-remitting subtypes-and Parkinson's disease. Patient demographics reveal distinct usage patterns across adult, geriatric and pediatric cohorts, while sales channels, whether offline through hospital and retail pharmacies or online platforms, shape distribution dynamics. Finally, end users spanning clinics, contract research organizations, hospitals and research institutes drive demand based on clinical and investigational needs.

Together, these segmentation insights empower leaders to align product development, pricing models and market entry strategies with the diverse needs of stakeholders across the value chain.

Uncovering Key Regional Dynamics Shaping Neurodegenerative Drug Adoption Patterns and Investment Priorities Across Major Geographies

Regional dynamics exert a profound influence on the trajectory of neurodegenerative drug adoption and investment. In the Americas, robust research infrastructure and significant public and private funding have accelerated the development of cutting-edge therapeutics, while established reimbursement frameworks support commercial scalability. Market participants in this region are leveraging advanced clinical trial networks and post-market surveillance programs to validate real-world outcomes and reinforce market access.

Across Europe, the Middle East and Africa, heterogeneous regulatory environments present both challenges and opportunities. Countries with streamlined approval pathways and patient access schemes foster innovation, whereas regions with constrained healthcare budgets demand tailored cost-benefit justifications. Geographic nuances in disease prevalence, healthcare spending and care delivery models further guide strategic partnerships and localized R&D initiatives.

The Asia-Pacific region is characterized by rapid urbanization, rising healthcare expenditure and expanding clinical trial capacity. A growing middle-class population and favorable policy incentives are attracting global players to establish manufacturing hubs and research centers. Local regulatory bodies are increasingly harmonizing guidelines with international standards, promoting faster market entry for novel therapies. Understanding these distinct regional landscapes enables stakeholders to optimize portfolio allocation, forge strategic alliances and adapt commercialization strategies to the unique parameters of each geography.

Highlighting Leading Industry Players Driving Innovation Partnerships and Competitive Strategies in the Neurodegenerative Drug Market

Within the neurodegenerative drug arena, certain organizations stand out for their pioneering approaches to research, development and commercialization. These industry leaders leverage cross-disciplinary collaborations, integrating academic insights with in-house R&D capabilities to accelerate candidate selection and preclinical validation. Strategic alliances with biotechnology firms and technology providers have allowed them to harness advanced analytics and artificial intelligence, optimizing trial design and patient recruitment strategies.

Furthermore, these companies are redefining the competitive landscape through targeted acquisitions and licensing agreements, expanding their pipelines to include both disease-modifying and symptomatic treatments. Their focus on specialty formulations and novel delivery systems has improved therapeutic outcomes and patient adherence. In parallel, they maintain robust portfolios of biomarkers and companion diagnostics, enabling more precise patient stratification and personalized care models.

To sustain their market leadership, these players continually strengthen their global footprint. They invest in manufacturing capacity, secure strategic partnerships for distribution, and engage proactively with regulatory agencies to navigate complex approval pathways. By combining financial resilience with scientific excellence, these companies set the benchmark for innovation, operational efficiency and commercial success in the neurodegenerative drug sector.

Formulating Actionable Strategic Recommendations for Industry Leaders to Navigate Evolving Market Landscapes and Regulatory Environments

To thrive in the dynamic field of neurodegenerative therapeutics, industry leaders must adopt a multi-faceted strategic approach. First, prioritizing investment in cutting-edge R&D initiatives, including gene therapies, biomarker-driven platforms and digital health integrations, will position organizations at the forefront of innovation. Second, diversifying supply chains by establishing regional manufacturing hubs and securing alternative sourcing agreements can mitigate the financial and operational risks associated with tariff fluctuations and geopolitical shifts.

In addition, fostering collaborative ecosystems with technology partners, academic centers and patient advocacy groups will accelerate translational research and enhance stakeholder engagement. This collaborative ethos should extend to regulatory strategy, where early dialogue with health authorities can streamline approval pathways and align clinical trial endpoints with payer expectations. Moreover, implementing patient-centric programs that support adherence, education and long-term outcomes will strengthen market access and underpin value-based care models.

Finally, organizations must refine their commercial strategies through dynamic pricing frameworks and adaptive go-to-market plans that reflect regional nuances and evolving reimbursement landscapes. By executing these recommendations, industry leaders can navigate uncertainties, capitalize on emerging opportunities and deliver meaningful therapeutic advances to patients living with neurodegenerative conditions.

Detailing a Robust Research Methodology Integrating Multidimensional Data Sources Expert Analyses and Rigorous Validation Processes

This study employs a comprehensive research methodology designed to deliver actionable insights and reliable analysis. The foundation rests on extensive secondary research, incorporating peer-reviewed journals, regulatory filings and clinical trial databases to map the current state of neurodegenerative drug development. Building on this, primary research engagements with key opinion leaders, including neurologists, pharmacologists and patient advocacy representatives, provide nuanced perspectives on therapeutic needs and adoption trends.

Quantitative analysis leverages real-world evidence and proprietary datasets, employing statistical validation techniques to ensure data integrity and reproducibility. Qualitative insights from expert interviews and roundtable discussions enrich the quantitative findings, identifying emerging themes and potential inflection points. The methodology also includes a thorough review of policy frameworks, trade agreements and tariff schedules to assess regulatory impacts on supply chains and pricing structures.

Data triangulation and scenario analysis further validate the robustness of conclusions, while peer benchmarking and portfolio mapping contextualize competitive positioning. This multi-dimensional approach ensures that the study's conclusions are grounded in empirical evidence, expert judgment and strategic foresight, equipping stakeholders with the insights needed to make informed decisions in the neurodegenerative drug domain.

Synthesizing Core Findings and Strategic Implications to Guide Stakeholder Decisions in the Neurodegenerative Drug Domain

The synthesis of this analysis underscores the transformative trajectories reshaping neurodegenerative drug development. Scientific breakthroughs in molecular targeting and biomarker identification are complemented by regulatory innovations that accelerate patient access. At the same time, evolving tariff policies and supply chain dynamics necessitate adaptive operational strategies to maintain cost efficiency and global competitiveness.

Segmenting the market by drug type, class, administration mode, mechanism of action, therapeutic approach, indication, demographics, sales channel and end user reveals the nuanced pathways to value creation. Regionally tailored strategies highlight the importance of understanding local regulatory frameworks, reimbursement models and healthcare infrastructure. Leading industry players demonstrate the competitive advantages of strategic partnerships, pipeline diversification and technology integration.

Actionable recommendations emphasize the need for investment in advanced R&D, supply chain resilience, collaborative ecosystems, regulatory engagement and patient-centric care models. Rigorous methodological validation ensures that these insights are not only evidence-based but also forward-looking, preparing stakeholders to navigate future uncertainties. This conclusion ties together the study's core findings, offering a clear roadmap for decision-makers seeking to capitalize on the opportunities presented by the evolving landscape of neurodegenerative therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurodegenerative Drugs Market, by Type

  • 8.1. Branded
  • 8.2. Generics

9. Neurodegenerative Drugs Market, by Drug Class

  • 9.1. Cholinesterase Inhibitors
    • 9.1.1. Donepezil
    • 9.1.2. Pyridostigmine
    • 9.1.3. Rivastigmine
  • 9.2. Decarboxylase Inhibitors
    • 9.2.1. Benserazide
    • 9.2.2. Carbidopa
    • 9.2.3. Methyldopa
  • 9.3. Dopamine Agonist
    • 9.3.1. Apomorphine
    • 9.3.2. Cabergoline
    • 9.3.3. Pramipexole
    • 9.3.4. Rotigotine
  • 9.4. Immunomodulators

10. Neurodegenerative Drugs Market, by Mode Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Transdermal Patch

11. Neurodegenerative Drugs Market, by Mechanism Of Action

  • 11.1. Ion Channel Modulators
    • 11.1.1. Potassium Channel Modulators
    • 11.1.2. Sodium Channel Modulators
  • 11.2. Synaptic Modulators

12. Neurodegenerative Drugs Market, by Therapeutic Approach

  • 12.1. Neuroprotection
    • 12.1.1. Anti-Inflammatory Agents
    • 12.1.2. Antioxidants
  • 12.2. Preventive Treatment
  • 12.3. Symptomatic Treatment

13. Neurodegenerative Drugs Market, by Indication

  • 13.1. Alzheimer's Disease
  • 13.2. Amyotrophic Lateral Sclerosis (ALS)
  • 13.3. Multiple Sclerosis
    • 13.3.1. Primary Progressive
    • 13.3.2. Relapsing-Remitting
  • 13.4. Parkinson's Disease

14. Neurodegenerative Drugs Market, by Patient Demographics

  • 14.1. Adult
  • 14.2. Geriatric
  • 14.3. Pediatric

15. Neurodegenerative Drugs Market, by Sales Channel

  • 15.1. Offline
    • 15.1.1. Hospitals Pharmacies
    • 15.1.2. Retail Pharmacies
  • 15.2. Online

16. Neurodegenerative Drugs Market, by End User

  • 16.1. Clinics
  • 16.2. Contract Research Organizations
  • 16.3. Hospitals
  • 16.4. Research Institutes

17. Neurodegenerative Drugs Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Neurodegenerative Drugs Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Neurodegenerative Drugs Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. United States Neurodegenerative Drugs Market

21. China Neurodegenerative Drugs Market

22. Competitive Landscape

  • 22.1. Market Concentration Analysis, 2025
    • 22.1.1. Concentration Ratio (CR)
    • 22.1.2. Herfindahl Hirschman Index (HHI)
  • 22.2. Recent Developments & Impact Analysis, 2025
  • 22.3. Product Portfolio Analysis, 2025
  • 22.4. Benchmarking Analysis, 2025
  • 22.5. Abbott Laboratories
  • 22.6. AbbVie Inc.
  • 22.7. ACADIA Pharmaceuticals Inc.
  • 22.8. Alpha Cognition Inc.
  • 22.9. Amneal Pharmaceuticals, Inc.
  • 22.10. Aquinnah Pharmaceuticals Inc.
  • 22.11. Asceneuron SA
  • 22.12. AstraZeneca PLC
  • 22.13. AZTherapies, Inc.
  • 22.14. Bausch Health Companies Inc.
  • 22.15. Biogen Inc.
  • 22.16. Boehringer Ingelheim International GmbH
  • 22.17. Denali Therapeutics Inc.
  • 22.18. Eli Lilly and Company
  • 22.19. GlaxoSmithKline PLC
  • 22.20. H. Lundbeck A/S
  • 22.21. Johnson & Johnson Services, Inc.
  • 22.22. Kyowa Kirin International plc
  • 22.23. Lupin Limited
  • 22.24. Merck & Co., Inc.
  • 22.25. Novartis AG
  • 22.26. Orion Corporation by Smiths Group plc
  • 22.27. Pfizer, Inc.
  • 22.28. Sanofi SA
  • 22.29. Takeda Pharmaceutical Company Limited
  • 22.30. Theravance Biopharma
  • 22.31. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEURODEGENERATIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 17. CHINA NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GENERICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DONEPEZIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DONEPEZIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RIVASTIGMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RIVASTIGMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BENSERAZIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BENSERAZIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BENSERAZIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CARBIDOPA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CARBIDOPA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CARBIDOPA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY METHYLDOPA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY METHYLDOPA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY METHYLDOPA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY APOMORPHINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY APOMORPHINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY APOMORPHINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CABERGOLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CABERGOLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CABERGOLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ROTIGOTINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ROTIGOTINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ROTIGOTINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY POTASSIUM CHANNEL MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY POTASSIUM CHANNEL MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY POTASSIUM CHANNEL MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SODIUM CHANNEL MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SODIUM CHANNEL MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SODIUM CHANNEL MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYNAPTIC MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYNAPTIC MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYNAPTIC MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTIOXIDANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTIOXIDANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS (ALS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS (ALS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS (ALS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RELAPSING-REMITTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RELAPSING-REMITTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RELAPSING-REMITTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 309. GCC NEURODEGENE